Characteristics | Percentage of Patients (n/n) | Methylation frequency of TRPM7(n/n) |
---|---|---|
Age,years | ||
 Mean | 51.5 | n/a |
 SD | 11.5 | n/a |
WHO grade | ||
 I | 3.2(7/219) | 28.6(2/7) |
 II | 74.4(163/219) | 45.4(74/163) |
 III | 22.4(49/219) | 34.7(17/49) |
Molecular Subtype | ||
 Luminal A | 35.6(78/219) | 33.3(26/78) |
 Luminal B | 32.0(70/219) | 45.7(32/70) |
 Her2+ | 14.6(32/219) | 46.9(15/32) |
 Basal like | 17.8(39/219) | 51.3(20/39) |
ER | ||
 - | 37.0(81/219) | 37.0(30/81) |
  +  | 63.0 (138/219) | 45.6(63/138) |
PR | ||
 - | 43.8(96/219) | 38.5(37/96) |
  +  | 56.2(123/219) | 45.5(56/123) |
Her2 | ||
 - | 78.1(171/219) | 45.0(77/171) |
  +  | 21.9(48/219) | 33.3(16/48) |
Lymph node metastasis (LNM) | ||
 No | 69.8(153/219) | 56.2(86/153) |
 Yes | 30.2(66/219) | 10.6(7/66)* |
Radiotherapy | ||
 No | 51.6(113/219) | 54.0(61/113) |
 Yes | 48.4(106/219) | 30.2(32/106) |
Chemotherapy | ||
 No | 14.2(31/219) | 54.8(17/31) |
 Yes | 85.8(188/219) | 40.4(76/188) |
Recurrence | ||
 No | 84.9(186/219) | 44.6(83/186) |
 Yes | 15.1(33/219) | 30.3(10/33) * |
Survival status | ||
 Alive | 82.6(181/219) | 45.3(82/181) |
 Dead | 17.4(38/219) | 28.9(11/38)* |